Evidence map›Paper›PMID 16048914›Full record

ArticleAntimicrobial agents and chemotherapy2005

Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.

Charles R Dean, Shubha Narayan, Denis M Daigle, JoAnn L Dzink-Fox, Xiaoling Puyang, Kathryn R Bracken, Karl E Dean, Beat Weidmann, Zhengyu Yuan, Rakesh Jain and 1 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Imipenem heteroresistance but not tolerance inFrontiers in microbiology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Peptide deformylase inhibitors as potent antimycobacterial agents.Antimicrobial agents and chemotherapy · 2006
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Charles R DeanInfectious Diseases, Novartis Institute for Biomedical Research, Inc., 100 Technology Square, Cambridge, MA 02139, USA. charlesr.dean@novartis.com
Shubha Narayan
Denis M Daigle
JoAnn L Dzink-Fox
Xiaoling Puyang
Kathryn R Bracken
Karl E Dean
Beat Weidmann
Zhengyu Yuan
Rakesh Jain
Neil S Ryder

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haemophilus influenzae isolates vary widely in their susceptibilities to the peptide deformylase inhibitor LBM415 (MIC range, 0.06 to 32 microg/ml); however, on average, they are less susceptible than gram-positive organisms, such as Staphylococcus aureus and Streptococcus pneumoniae. Insertional inactivation of the H. influenzae acrB or tolC gene in strain NB65044 (Rd strain KW20) increased susceptibility to LBM415, confirming a role for the AcrAB-TolC pump in determining resistance. Consistent with this, sequencing of a PCR fragment generated with primers flanking the acrRA region from an LBM415-hypersusceptible H. influenzae clinical isolate revealed a genetic deletion of acrA. Inactivation of acrB or tolC in several clinical isolates with atypically reduced susceptibility to LBM415 (MIC of 16 microg/ml or greater) significantly increased susceptibility, confirming that the pump is also a determinant of decreased susceptibility in these clinical isolates. Examination of acrR, encoding the putative repressor of pump gene expression, from several of these strains revealed mutations introducing frameshifts, stop codons, and amino acid changes relative to the published sequence, suggesting that loss of pump repression leads to decreased susceptibility. Supporting this, NB65044 acrR mutants selected by exposure to LBM415 at 8 microg/ml had susceptibilities to LBM415 and other pump substrates comparable to the least sensitive clinical isolates and showed increased expression of pump genes.

Indexed as

AmidohydrolasesAnti-Bacterial AgentsBacterial Outer Membrane ProteinsBacterial ProteinsCarrier ProteinsDrug Resistance, BacterialEnzyme InhibitorsEscherichia coli ProteinsGene Expression Regulation, BacterialHaemophilus influenzaeHumansMembrane Transport ProteinsMicrobial Sensitivity TestsMutagenesis, InsertionalOligonucleotide Array Sequence AnalysisPeptidesAcrB protein, Salmonella entericaAcrR protein, Klebsiella pneumoniaeAmidohydrolasesAnti-Bacterial AgentsBacterial Outer Membrane ProteinsBacterial ProteinsCarrier ProteinsEnzyme InhibitorsEscherichia coli ProteinsMembrane Transport ProteinsNVP PDF 713peptide deformylasePeptidestolC protein, E coli

Identifiers

PMID16048914
PMCPMC1196275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.